References:
[1] Bartoli, M. et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol. Ther. 13, 250–259 (2006). [2] Cenni, V. et al. Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2). Mol. Biol. Cell 22, 2946–2956 (2011). [3] Laure, L. et al. A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor-κB pathway in skeletal muscle. FEBS J. 277, 4322–4337 (2010). [4] Mourkioti, F. & Rosenthal, N. NF-κB signaling in skeletal muscle: prospects for intervention in muscle diseases. Journal of Molecular Medicine 86, 747–759 (2008). |
[5] Richard, I. et al. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J. Cell Biol. 151, 1583–1590 (2000). [6] Quest Staff. A Promising New Development for Treatment of Duchenne Muscular Dystrophy. Quest Magazine. (2009). <http://quest.mda.org /news/promising-new-development-treatment-duchenne-muscular-dystrophy> |